Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: The English NHS Diabetic Eye Screening Programme was established in 2003. Eligible people are invited annually for digital retinal photography screening. Those found to have potentially sight-threatening diabetic retinopathy (STDR) are referred to surveillance clinics or to Hospital Eye Services. Objectives: To determine whether personalised screening intervals are cost-effective. Design: Risk factors were identified in Gloucestershire, UK using survival modelling. A probabilistic decision hidden (unobserved) Markov model with a misgrading matrix was developed. This informed estimation of lifetime costs and quality-adjusted life-years (QALYs) in patients without STDR. Two personalised risk stratification models were employed: two screening episodes (SEs) (low, medium or high risk) or one SE with clinical information (low, medium–low, medium–high or high risk). The risk factor models were validated in other populations. Setting: Gloucestershire, Nottinghamshire, South London and East Anglia (all UK). Participants: People with diabetes in Gloucestershire with risk stratification model validation using data from Nottinghamshire, South London and East Anglia. Main outcome measures: Personalised risk-based algorithm for screening interval; cost-effectiveness of different screening intervals. Results: Data were obtained in Gloucestershire from 12,790 people with diabetes with known risk factors to derive the risk estimation models, from 15,877 people to inform the uptake of screening and from 17,043 people to inform the health-care resource-usage costs. Two stratification models were developed: one using only results from previous screening events and one using previous screening and some commonly available GP data. Both models were capable of differentiating groups at low and high risk of development of STDR. The rate of progression to STDR was 5 per 1000 person-years (PYs) in the lowest decile of risk and 75 per 1000 PYs in the highest decile. In the absence of personalised risk stratification, the most cost-effective screening interval was to screen all patients every 3 years, with a 46% probability of this being cost-effective at a £30,000 per QALY threshold. Using either risk stratification models, screening patients at low risk every 5 years was the most cost-effective option, with a probability of 99-100% at a £30,000 per QALY threshold. For the medium-risk groups screening every 3 years had a probability of 43 –48% while screening high-risk groups every 2 years was cost-effective with a probability of 55–59%. Conclusions: The study found that annual screening of all patients for STDR was not cost-effective. Screening this entire cohort every 3 years was most likely to be cost-effective. When personalised intervals are applied, screening those in our low-risk groups every 5 years was found to be cost-effective. Screening high-risk groups every 2 years further improved the cost-effectiveness of the programme. There was considerable uncertainty in the estimated incremental costs and in the incremental QALYs, particularly with regard to implications of an increasing proportion of maculopathy cases receiving intravitreal injection rather than laser treatment. Future work should focus on improving the understanding of risk, validating in further populations and investigating quality issues in imaging and assessment including the potential for automated image grading. Study registration: Integrated Research Application System project number 118959. Funding details: The National Institute for Health Research Health Technology Assessment programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Stratton, I. M., Kohner, E. M., Aldington, S. J., Turner, R. C., Holman, R. R., Manley, S. E., & Matthews, D. R. (2001) · Diabetologia · doi:10.1007/s001250051594 · Cited by 1,019
Self-citationCollins, G. S., de Groot, J. A., Dutton, S., Omar, O., Shanyinde, M., Tajar, A., Voysey, M., Wharton, R., Yu, L.-M., Moons, K. G., et al. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-40 · Cited by 729
State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3
Siebert, U., Alagoz, O., Bayoumi, A. M., Jahn, B., Owens, D. K., Cohen, D. J., & Kuntz, K. M. (2012) · Value in Health · doi:10.1016/j.jval.2012.06.014 · Cited by 588
Hayes, A. J., Leal, J., Gray, A. M., Holman, R. R., & Clarke, P. M. (2013) · Diabetologia · doi:10.1007/s00125-013-2940-y · Cited by 495
Self-citationVijan, S. (2000) · JAMA · doi:10.1001/jama.283.7.889 · Cited by 295
Health utility values associated with diabetic retinopathy
Lloyd, A., Nafees, B., Gavriel, S., Rousculp, M. D., Boye, K. S., & Ahmad, A. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02430.x · Cited by 83
The economic burden of diabetic retinopathy in Germany in 2002
Happich, M., Reitberger, U., Breitscheidel, L., Ulbig, M., & Watkins, J. (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0573-x · Cited by 63
Cited by
Wong, T. Y., Cheung, C. M. G., Larsen, M., Sharma, S., & Simó, R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.12 · Cited by 1,094
Ting, D. S. W., Cheung, G. C. M., & Wong, T. Y. (2016) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.12696 · Cited by 1,066
Screening for diabetic retinopathy: new perspectives and challenges
Vujosevic, S., Aldington, S. J., Silva, P., Hernández, C., Scanlon, P., Peto, T., & Simó, R. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30411-5 · Cited by 671
Self-citationThe English National Screening Programme for diabetic retinopathy 2003–2016
Scanlon, P. H. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-0974-1 · Cited by 440
Self-citationCost-effectiveness of artificial intelligence screening for diabetic retinopathy in rural China
Huang, X.-M., Yang, B.-F., Zheng, W.-L., Liu, Q., Xiao, F., Ouyang, P.-W., Li, M.-J., Li, X.-Y., Meng, J., Zhang, T.-T., et al. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-07655-6 · Cited by 89
“Moreover, screening intervals have been found to have influence on cost-effectiveness in many countries [43–47].”
Background
Metadata
- Authors
- Scanlon, P. H., Aldington, S. J., Leal, J., Luengo-Fernandez, R., Oke, J., Sivaprasad, S., Gazis, A., & Stratton, I. M.
- Venue
- Health Technology Assessment
- Published
- 2015-09
- Volume
- 19
- Issue
- 74
- Pages
- 1-116
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2473407416
- Cited by
- 136
- References
- 9
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. https://app.cochat.ai/papers/10.3310/hta19740
- The paper
- Scanlon, P. H., Aldington, S. J., Leal, J., Luengo-Fernandez, R., Oke, J., Sivaprasad, S., Gazis, A., & Stratton, I. M. (2015). Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Health Technology Assessment. https://doi.org/10.3310/hta19740
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.